Category: Immucor Inc.Syndicate content

Bidding war for Carestream heats up | Wall Street Beat

March 29, 2013 by Brad Perriello

Private equity players Bain Capital, Carlyle Group and KKR & Co. are in the hunt for medical device company Carestream, said to be on the auction block for up to $3.5 billion. Wall Street Beat

At least 5 major private equity players are vying for medical device company Carestream Health, including Bain Capital, Carlyle Group and KKR & Co., according to Reuters.

Onex Corp. is hoping to unload Carestream, formed in the 2007 spinout of Eastman Kodak Co.'s healthcare business, for up to $3.5 billion, the news service reported.

Hologic sells Lifecodes to Immucor for $85M

January 4, 2013 by MassDevice staff

Immucor agrees to acquire Hologic's Lifecodes transplant diagnostics business in a deal worth up to $95 million, marking the 1st publicly reported acquisition by Immucor since former Medtronic CEO William Hawkins took the corner office.

M&A illustration

In-vitro diagnostics maker Immucor (NSDQ:BLUD) signed a definitive agreement to acquire the Lifecodes transplant diagnostics business of Hologic (NSDQ:HOLX) in a deal worth up to $95 million.

Former Medtronic CEO nets $8M in comp package during 2012

July 16, 2012 by MassDevice staff

Former Medtronic chairman & CEO Bill Hawkins receives more than $8 million in total compensation, including a $3.8 million lump severance payment, following his resignation from the corner office.

Bill Hawkins at MD headquarters

Former Medtronic (NYSE:MDT) chairman & CEO received more than $8 million in total compensation for his final year at the medical device titan, including a severance payment of about $3.8 million.

Moody's estimates med-tech tax impact

March 9, 2012 by MassDevice staff

Moody's Investor Services estimates that the impact of the medical device tax for the companies it covers will top $650 million. med-tech tax coverage

The 2.3% tax on revenues slated to go into effect next year for medical device makers could top $650 million for the med-tech companies covered by Moody's Investor Services, according to a report by the ratings agency.

The tax will help slow EBIDTA growth rates for the med-tech sector to between 1% and 4% over the next year to 18 months, according to Moody's, with organic growth rates of between 2% and 3% during that period.

Ex-Medtronic CEO Hawkins to chair new med-tech research center | Personnel Moves

March 2, 2012 by MassDevice staff

Former Medtronic CEO Bill Hawkins signs on as the inaugural chair for a new private-public med-tech regulatory science partnership for LifeScience Alley.

Bill Hawkins

Former Medtronic (NYSE:MDT) CEO Bill Hawkins will serve as the first chairman of a new private-public partnership aimed at improving development and testing of medical devices.

The partnership includes the Minnesota med-tech community, the FDA's Center for Devices & Radiological Health and the University of Minnesota to establish a regulatory science center in the North Star State.

Thoratec taps ex-Medtronic CEO Hawkins for board | Personnel Moves

December 16, 2011 by MassDevice staff

Thoratec Corp. appoints Immucor CEO and former Medtronic chief William Hawkins to its board of directors.


Cardiac device maker Thoratec Corp. (NSDQ:THOR) appointed former Medtronic (NYSE:MDT) CEO William Hawkins to its board of directors.

The current Immucor Inc. (NSDQ:BLUD) CEO brings more than 30 years of med-tech experience with him to the Pleasanton, Calif.-based boardroom.

Stu Randle talks to MassDevice, Immucor taps Hawkins, FDA spurs innovation, Lasik docs, Covidien's Thailand move, Medtronic in Puerto Rico, Med-tech starts overseas | +7

October 8, 2011 by MassDevice staff

The top seven medical device stories for the week of October 3, 2011.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.